SITE Centers (US:SITC) Prnewswire·2025-11-07 16:30Core Insights - Akeso, Inc. has presented preclinical research data for its novel monoclonal antibody AK135, targeting IL-1RAP, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer [1][2] Group 1: Product Development - AK135 effectively targets IL-1RAP and blocks three key pro-inflammatory signaling pathways—IL-1, IL-33, and IL-36, providing significant pain relief in neuropathy with good tolerability and safety profiles [2][6] - The antibody is currently in Phase I clinical trials for treating chemotherapy-induced peripheral neuropathy (CIPN) [6][11] - Preclinical studies indicate that AK135 shows dose-dependent efficacy in alleviating neuropathic pain and maintains stable body weight in treated models without significant toxicity [8] Group 2: Market Context - CIPN affects 50-90% of chemotherapy-treated patients, with 30-40% progressing to chronic neuropathic pain, highlighting the clinical significance of effective treatment options [5] - Akeso's development of AK135 addresses a critical gap in treatment options for CIPN, as current effective therapies are limited [5][6] Group 3: Company Overview - Akeso is a leading biopharmaceutical company focused on innovative biological medicines, with a robust pipeline of over 50 innovative assets across various disease areas, including cancer and autoimmune diseases [11] - The company has developed a comprehensive end-to-end drug development platform and has 24 candidates in clinical trials, including 15 bispecific/multispecific antibodies [11]